Acromegaly Update

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.

Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.

This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis — alongside cost-effectiveness data for pasireotide and updated pituitary tumor pathology tools.

Two important consensus-level papers from late April 2026 sharpen the standards for acromegaly diagnosis and comorbidity management, incorporating AI-assisted screening, ultrasensitive GH assays, and updated international expert guidance.

This week's acromegaly literature is headlined by a landmark cardiovascular disease review in Endocrine Reviews and a cluster of high-yield JCEM papers covering biomarker-guided therapy, standardized pituitary imaging, patient-reported quality of life, and histological predictors of surgical remission.